Ultragenyx Pharmaceutical Inc.
Congress has disclosed 5 buys and 0 sells of RARE (Ultragenyx Pharmaceutical Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying RARE and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-09-29 | $15.32 | $16.29 | +6.3% | ↩ near entry |
Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Legislation Related Legislation
Recent bills in this stock's sector (). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
5 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | BUY ◆ insider divergence | Self · 150 Main Street Trust > Bank of America | 2026-09-29 | 10 days | +1.0% | $1K–$15K 0.1% of NW |
60.2 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence · moderate | Self · 150 Main Street Trust > Bank of America | 2026-03-03 | 34 days | +3.6% | $1K–$15K 0.1% of NW |
9.5 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence · moderate | Self · 150 Main Street Trust > Bank of America | 2026-02-18 | 16 days | +3.9% | $1K–$15K 0.1% of NW |
14.4 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence | Self · 150 Main Street Trust > Bank of America | 2025-08-08 | 31 days | +14.4% | $1K–$15K 0.1% of NW |
27.3 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence | Self · 150 Main Street Trust > Bank of America | 2025-07-15 | 29 days | +6.5% | $1K–$15K 0.1% of NW |
63.1 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in RARE — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in RARE, 0 coincided with corporate insiders moving the same way within 60 days, and 5 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-15 | Horn Howard | C-suite | SELL | $108K | ↗ EDGAR |
| 2026-09-15 | Huizenga Theodore Alan | C-suite | SELL 10b5-1 | $17K | ↗ EDGAR |
| 2026-09-03 | Huizenga Theodore Alan | C-suite | SELL | $2K | ↗ EDGAR |
| 2026-08-03 | Horn Howard | C-suite | SELL 10b5-1 | $117K | ↗ EDGAR |
| 2026-08-03 | Parschauer Karah Herdman | C-suite | SELL 10b5-1 | $47K | ↗ EDGAR |
| 2026-07-01 | Horn Howard | C-suite | SELL 10b5-1 | $156K | ↗ EDGAR |
| 2026-06-15 | Parschauer Karah Herdman | C-suite | SELL 10b5-1 | $47K | ↗ EDGAR |
| 2026-06-15 | Sanders Corazon (Corsee) D. | Director | SELL | $50K | ↗ EDGAR |
| 2026-06-01 | Horn Howard | C-suite | SELL 10b5-1 | $111K | ↗ EDGAR |
| 2026-05-18 | SULIMAN SHEHNAAZ | Director | SELL 10b5-1 | $144K | ↗ EDGAR |
| 2026-05-05 | Crombez Eric | C-suite | SELL | $9K | ↗ EDGAR |
| 2026-05-01 | Horn Howard | C-suite | SELL 10b5-1 | $117K | ↗ EDGAR |
| 2026-04-01 | Horn Howard | C-suite | SELL 10b5-1 | $98K | ↗ EDGAR |
| 2026-03-10 | Parschauer Karah Herdman | C-suite | SELL | $80K | ↗ EDGAR |
| 2026-03-06 | Parschauer Karah Herdman | C-suite | SELL | $129K | ↗ EDGAR |
| 2026-03-03 | Horn Howard | C-suite | SELL 10b5-1 | $37K | ↗ EDGAR |
| 2026-03-02 | Crombez Eric | C-suite | SELL | $160K | ↗ EDGAR |
| 2026-03-02 | Horn Howard | C-suite | SELL 10b5-1 | $121K | ↗ EDGAR |
| 2026-03-02 | Horn Howard | C-suite | SELL 10b5-1 | $70K | ↗ EDGAR |
| 2026-03-02 | Huizenga Theodore Alan | C-suite | SELL | $37K | ↗ EDGAR |
| 2026-03-02 | Parschauer Karah Herdman | C-suite | SELL | $185K | ↗ EDGAR |
| 2026-03-02 | KAKKIS EMIL D | C-suite | SELL | $1.2M | ↗ EDGAR |
| 2026-03-02 | Harris Erik | C-suite | SELL | $240K | ↗ EDGAR |
| 2026-03-02 | Pinion John Richard | Other | SELL | $229K | ↗ EDGAR |
| 2026-02-02 | Horn Howard | C-suite | SELL 10b5-1 | $72K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-15 | Horn Howard C-suite | SELL | $108K |
| Congress | 2026-09-29 | Gilbert Cisneros | BUY | $1K–$15K |
| ◆ insider | 2026-09-15 | Huizenga Theodore Alan C-suite 10b5-1 | SELL | $17K |
| ◆ insider | 2026-09-03 | Huizenga Theodore Alan C-suite | SELL | $2K |
| ◆ insider | 2026-08-03 | Horn Howard C-suite 10b5-1 | SELL | $117K |
| ◆ insider | 2026-08-03 | Parschauer Karah Herdman C-suite 10b5-1 | SELL | $47K |
| ◆ insider | 2026-07-01 | Horn Howard C-suite 10b5-1 | SELL | $156K |
| ◆ insider | 2026-06-15 | Parschauer Karah Herdman C-suite 10b5-1 | SELL | $47K |
| ◆ insider | 2026-06-15 | Sanders Corazon (Corsee) D. Director | SELL | $50K |
| ◆ insider | 2026-06-01 | Horn Howard C-suite 10b5-1 | SELL | $111K |
| ◆ insider | 2026-05-18 | SULIMAN SHEHNAAZ Director 10b5-1 | SELL | $144K |
| ◆ insider | 2026-05-05 | Crombez Eric C-suite | SELL | $9K |
| ◆ insider | 2026-05-01 | Horn Howard C-suite 10b5-1 | SELL | $117K |
| ◆ insider | 2026-04-01 | Horn Howard C-suite 10b5-1 | SELL | $98K |
| ◆ insider | 2026-03-10 | Parschauer Karah Herdman C-suite | SELL | $80K |
| ◆ insider | 2026-03-06 | Parschauer Karah Herdman C-suite | SELL | $129K |
| Congress | 2026-03-03 | Gilbert Cisneros | BUY | $1K–$15K |
| ◆ insider | 2026-03-03 | Horn Howard C-suite 10b5-1 | SELL | $37K |
| ◆ insider | 2026-03-02 | Crombez Eric C-suite | SELL | $160K |
| ◆ insider | 2026-03-02 | Horn Howard C-suite 10b5-1 | SELL | $121K |
| ◆ insider | 2026-03-02 | Horn Howard C-suite 10b5-1 | SELL | $70K |
| ◆ insider | 2026-03-02 | Huizenga Theodore Alan C-suite | SELL | $37K |
| ◆ insider | 2026-03-02 | Parschauer Karah Herdman C-suite | SELL | $185K |
| ◆ insider | 2026-03-02 | KAKKIS EMIL D C-suite | SELL | $1.2M |
FAQ Common questions
How much has Congress traded RARE?
5 disclosed buys and 0 sells of RARE (Ultragenyx Pharmaceutical Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade RARE?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.